west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "过继免疫治疗" 3 results
  • 多发性骨髓瘤过继细胞免疫治疗的研究进展

    【摘要】 多发性骨髓瘤(multiple myeloma, MM)是严重威胁健康的恶性浆细胞疾病,主要的治疗方法是传统化学疗法,但其疗效有限,患者生活质量低,预后差。免疫治疗是一种新兴的有望在未来彻底消灭肿瘤细胞的治疗手段,过继细胞免疫治疗(adoptive cellular immunotherapy, ACI)更是经体内及体外都证实了具有强大的抗瘤作用。ACI与其他治疗手段的有机结合和合理安排将对MM的治疗带来新的曙光。现就目前开展的ACI治疗MM的前沿研究予以综述。

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • The Effect of CD3AK Cells on T Lymphocyte Subsets and Its Functions of Patients with Primary Liver Carcinoma

    Objective To explore the effect of CD3AK cells on T lymphocyte subsets and its functions of patients with primary liver carcinoma (PLC). MethodsFiftyeight patients with PLC were divided into two groups, CD3AK group (n=37), control group (n=21). Eleven blood donors were taken as normal control. All patients from the treatment group were given 2×109 CD3AK cells once a day for 5 days on the 1st day after operation, having received IL2 at a dose of 100 units per 24 hour by intravenous injection starting 30 minutes before administration of CD3AK cells. T lymphocyte subsets, IL2R, NK activity, LAK activity and proliferative activity were determined. ResultsThe CD4/CD8 ratio, expression of IL2R, proliferative activity, NK activity and LAK activity of T lymphocytes from the treatment group were significantly higher than those of control respectively.Conclusion The adoptive transfer of CD3AK cells could improve the disorder of T lymphocyte subsets and its functions and provide the patients with PLC with fresh abundant effectors against tumor.

    Release date:2016-08-28 05:11 Export PDF Favorites Scan
  • A REPORT ON THE TREATMENT OF PATIENTS WITH ADVANCED PRIMARY LIVER CANCER USING INTERLEUKIN-2 AND LYPHOKINE ACTIVATED KILLER CELLS COMVINED WITH SURGERY OR CHMOTHERAPY

    31 case of advanced primary liver cancer were treated by using IL-2 and LAK cells in which 15 cases were combined with surgery (group A) and 16 cases were combined with chemotherpy (Group B). 7~14 months follow-up showed: In group A there was no recurence and metastasis, and the cell-mediated immunity was obviously improved. In group B, the average life time was more than 5.84 months, the tumor average diameter dicreased in 10 cases ,and the cee-mediated immunity was also improved. The role of immunotherapy combined with surgery or chemotherapy was discussed.

    Release date:2016-08-29 04:26 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content